FDAapproval65% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (melanoma) as Bristol-Myers Squibb.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Melanoma
- Sub-indication
- Melanoma
Related signal: Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma